Provided by Tiger Trade Technology Pte. Ltd.

ANTENGENE-B

3.355
-0.145-4.14%
Volume:786.50K
Turnover:2.64M
Market Cap:2.30B
PE:-7.54
High:3.500
Open:3.500
Low:3.300
Close:3.500
52wk High:6.790
52wk Low:2.760
Shares:686.00M
HK Float Shares:686.00M
Volume Ratio:1.71
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.445
ROE:6.39%
ROA:7.18%
PB:2.15
PE(LYR):-7.54
PS:3.48

Loading ...

ANTENGENE-B to Initiate On-Market Share Buyback Program

Stock News
·
Jun 25

Antengene Plans up to HK$50 Million On-market Share Buyback

Reuters
·
Jun 25

Antengene Corp - Intends to Repurchase up to 67.92 Mln Shares

THOMSON REUTERS
·
Jun 25

Antengene Corp - Board Resolves to Repurchase Shares up to HK$50 Mln Aggregate Consideration

THOMSON REUTERS
·
Jun 25

Antengene to Spin Off TCE Assets into New Entity for Global Expansion

Deep News
·
Jun 22

BRIEF-Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106

Reuters
·
Jun 22

Antengene-B Inks Exclusive Licensing Deal with K2 Therapeutics for ATG-106 and Grants Option for Undisclosed Bispecific TCE

Stock News
·
Jun 22

Antengene clinches USD 20.00 million global licensing deal with K2 Therapeutics for ATG-106; milestones may add USD 960.50 million and mirrors terms for optional second TCE

Bulletin Express
·
Jun 22

Antengene licenses ATG-106 bispecific T-cell engager to MPM BioImpact’s K2 Therapeutics for USD 20 million upfront

Reuters
·
Jun 22

Antengene Corp - to Receive About $20 Mln Upfront and Near-Term Consideration

THOMSON REUTERS
·
Jun 22

Antengene Corp - Enters Exclusive License Agreement With K2 Therapeutics for Atg-106

THOMSON REUTERS
·
Jun 22

Antengene-B Announces Appointment of New Co-Company Secretaries

Stock News
·
Jun 10

Antengene Reshuffles Joint Company Secretaries and Secures Three-Year HKEX Compliance Waiver

Bulletin Express
·
Jun 10

Antengene names Ying Liu, Chin Hei Lam as joint company secretaries, replacing Yang Cao, Wai Chiu Wong

Reuters
·
Jun 10

BRIEF-Antengene Says China NMPA Approves IND Application For Phase I Study Of ATG-201

Reuters
·
Jun 10

Antengene Secures China IND Approval for Autoimmune Disease Drug

MT Newswires Live
·
Jun 10

ANTENGENE-B Receives Chinese IND Approval for ATG-201 in Autoimmune Disease Treatment

Stock News
·
Jun 10

Antengene Gains NMPA IND Clearance for ATG-201 CD19×CD3 T-Cell Engager Targeting Autoimmune Diseases

Bulletin Express
·
Jun 10

Antengene - China Nmpa Approves Ind Application for Phase I Study of Atg-201

THOMSON REUTERS
·
Jun 10

Antengene to present first preclinical data on ATG-207 autoimmune drug candidate at EULAR 2026

Reuters
·
Jun 03